NCT00857909

The Effect of Amiloride and Spironolactone in Healthy Persons

The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Regional Hospital Holstebro · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.

Detailed description

The purpose is to measure the effect of amiloride and spironolactone on: 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsbewave velocity, augmentation index and central blood pressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory blood pressure

Conditions

• High Blood Pressure

Interventions

Type	Name	Description
DRUG	Amiloride	1 tablet twice a day
DRUG	Spironolactone	1 tablet twice a day
DRUG	Placebo	Placebo
DRUG	Placebo and spironolactone	5mg twice daily
DRUG	Spironolactone	25mg twice daily

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2009-03-09
• Last updated: 2011-07-08

Locations

1 site across 1 country: Denmark